Genmab


FY20 ends on a high; cost base to increase in FY21

24/02/21 -"FY20 sales and operating profit targets were exceeded, led by higher Darzalex royalties and lower R&D costs. Given its convenience dosing, Darzalex should hit the $5bn sales mark in FY21 (vs. ..."

Pages
54
Language
English
Published on
24/02/21
You may also be interested by these reports :
24/03/21
Roche has provided a re-assuring update for its Diagnostics division. Besides leveraging the COVID-19 testing opportunity, the group is ...

19/03/21
Faes’ FY20 reported earnings benefited from higher milestone income and lower operating costs (reduction in commercial, travelling, and marketing ...

16/03/21
Concerns surrounding the EU’s COVID-19 vaccination campaign refuse to die down. With AstraZeneca now reporting a safety scare – after already ...

15/03/21
Merck KGaA (Add, Germany) belongs to those groups that enjoy the benefit of a long-term view thanks to absolute family control but are nominally ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO